Core Insights - Polyrizon Ltd. announced positive results from a pre-clinical study evaluating its PL-14 Allergy Blocker formulation, demonstrating its effectiveness in blocking allergens compared to hydroxypropyl methylcellulose (HPMC) [1][5]. Study Findings - The study utilized a validated in-vitro Transwell permeability system to assess PL-14's ability to inhibit the transfer of Der p 1, a significant house dust mite allergen associated with allergic rhinitis and asthma [2]. - PL-14 significantly reduced allergen transfer at all time points compared to HPMC, with statistical significance (p-values ≤ 0.0042) observed at 1, 2, 4, 6, and 24 hours [3][9]. - At 1 hour, PL-14 showed a mean allergen concentration of approximately 20.6 ng, while HPMC had a concentration of about 1354.4 ng. By 24 hours, HPMC's concentration rose to around 5201.2 ng, indicating limited barrier function [9]. Product Development - The results support the continued advancement of PL-14 as a preventive approach for allergic rhinitis by reducing allergen penetration through a synthetic surface [6]. - Polyrizon is advancing its preclinical development program and plans to support future clinical studies to establish PL-14's regulatory pathway and clinical benefits for allergy prevention [6]. Company Overview - Polyrizon is a development-stage biotechnology company focused on innovative medical device hydrogels delivered as nasal sprays, creating a barrier against viruses and allergens [7]. - The company's proprietary Capture and Contain TM hydrogel technology aims to function as a "biological mask" in the nasal cavity, with ongoing development to enhance bioadhesion and retention for drug delivery [7].

Taipei, Taiwan, Jan. 05, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today announced the successful completion of critical milestones across its core platforms: stem cell therapy & exosome platforms focused on ophthalmology conditions, early cancer detection powered by DNA methylation and next-generation precision diagnostics. The Company also outlined a ...

Core Viewpoint - Humacyte, Inc. plans to file a Marketing Authorization Application (MAA) with the Israel Ministry of Health for its acellular tissue engineered vessel (ATEV™ or Symvess) aimed at arterial trauma repair, with expectations for expedited commercialization in other regions following FDA approval [1][2]. Group 1: Expansion Plans - The expansion of Symvess is driven by requests from surgeons and hospitals in Israel, with plans to extend into Europe and the Middle East [1][2]. - The company anticipates that the FDA approval of Symvess will facilitate faster commercialization pathways in these new territories [2]. Group 2: Clinical Data and Product Features - Positive three-year results from the V005 Phase 2/3 study of Symvess in extremity vascular repair provide the first long-term data in traumatic arterial repair using a biologic conduit [2]. - Symvess is designed to be available off-the-shelf, which is crucial for saving surgical time in emergency situations, and has shown low infection rates and high limb salvage rates [2]. Group 3: Company Overview - Humacyte is focused on developing universally implantable bioengineered human tissues and has received FDA approval for its ATEV in December 2024 for vascular trauma [3]. - The company is also conducting late-stage clinical trials for other vascular applications and has received various designations from the FDA, including Regenerative Medicine Advanced Therapy (RMAT) [3].

WALTHAM, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherland, MD, Chief Executive Officer of Upstream Bio, will be presenting at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, at 2:15 p.m. PT. A live webcast of the presentation will be available under the Events tab on the Investors section ...

JADE101 Phase 1 healthy volunteer trial ongoing; biomarker-rich interim data expected in the first half of 2026 Phase 2 clinical trial of JADE101 in patients with IgA nephropathy expected to begin mid-2026; preliminary data anticipated in 2027JADE201, a half-life extended afucosylated anti-BAFF receptor antibody, expected to advance into first-in-human study in rheumatoid arthritis patients in the second quarter of 2026; interim data anticipated in 2027Third development candidate, JADE301, nominated; curren ...

Core Viewpoint - ProPhase Labs, Inc. is addressing recent stock price volatility attributed to technical factors, including convertible debt conversion and a reverse stock split, while emphasizing the stability of its underlying asset value [2][3][5]. Group 1: Stock Price Volatility - The company believes that recent stock price fluctuations are due to short-term technical factors, such as the conversion and resale of convertible debt and the transition from Nasdaq to the OTC market [2]. - Over $3.3 million of the $3.8 million convertible debt has been converted, leading to a reduction in company debt and an increase in shareholders' equity [3]. - The remaining unconverted balance of convertible debt is less than $500,000, and recent conversions occurred at a price of approximately $0.76 per share, which is above the current trading price [4]. Group 2: Financial Health and Asset Value - The conversion of debt has increased the number of outstanding shares but has also reduced liabilities, thereby strengthening the company's balance sheet [5]. - The intrinsic value of ProPhase Labs' assets remains unchanged despite the capital structure changes, with significant underlying value in its operating subsidiaries and assets [5]. - The company is focused on stabilizing its capital structure and advancing core business operations, indicating that recent trading volatility does not reflect changes in long-term strategy or growth prospects [5]. Group 3: Company Overview - ProPhase Labs is a biotech and consumer products company focused on innovative healthcare solutions, including Whole Genome Sequencing and diagnostic tests [7]. - The company aims to revolutionize healthcare and is committed to executional excellence and smart diversification [7].

Core Insights - Insilico Medicine, a newly listed biotech firm in Hong Kong, is set to receive up to US$888 million from a partnership with French drug maker Servier to utilize its AI platform for cancer drug development [1][2] - The partnership includes up to US$32 million in upfront and near-term R&D payments, with additional payments based on achieving specific milestones [2] - Insilico's AI-driven drug discovery platform can potentially reduce drug development timelines to 12 to 18 months, compared to the traditional average of 4.5 years [3] Company Overview - Insilico Medicine's IPO raised HK$2.28 billion (US$293 million) and was oversubscribed 1,427 times, indicating strong market interest [1] - The company's generative AI platform creates new drug molecules from scratch by interpreting genomics and biological data, rather than screening existing chemical libraries [4] - Insilico's shares experienced a slight decline of 0.7% to HK$37.30 shortly after the IPO [4] Industry Context - The partnership with Servier highlights a growing trend in the healthcare sector, where companies are increasingly leveraging advanced technologies to meet unmet medical needs [5] - The Hong Kong stock exchange has seen a surge in healthcare listings, driven by favorable policies and collaborations between mainland drug developers and global pharmaceutical companies [4]

Core Viewpoint - The 2025 IPO market shows significant recovery compared to the low point in 2024, with a total of 297 IPOs across A-shares, Hong Kong, and the US markets, marking a notable increase in activity [2][51]. Group 1: IPO Market Overview - The Hong Kong market emerged as the largest IPO market globally in 2025, with 117 companies listed, a nearly 70% increase from 69 in 2024 [2][52]. - A-shares also saw a recovery, with 113 companies listed, up 13% from 100 in 2024, raising a total of 131.77 billion yuan, a 95.6% increase from 673.53 billion yuan in 2024 [52]. - The US market for Chinese companies remained subdued, with only 67 companies listed, raising approximately 8.03 billion yuan, significantly lower than the 18.56 billion yuan in 2024 [53]. Group 2: Investment Institutions - The "TOP100" list for 2025 includes 17 institutions that made the list for the first time in six years, while 18 institutions have maintained their presence for six consecutive years [51]. - The average number of IPO projects per institution in the TOP100 was 4.85, up from 3.19 in 2024, indicating a recovery in market activity [51]. - The threshold for inclusion in the TOP100 was set at 2 IPO projects, compared to 1 in 2024 [51]. Group 3: Fundraising and Project Distribution - The total fundraising amount in the Hong Kong market reached 261.53 billion yuan, a 218.6% increase from 82.1 billion yuan in 2024 [52]. - The average fundraising size for IPOs in Hong Kong was 2.255 billion yuan, significantly higher than 1.19 billion yuan in 2024 [56]. - The top fundraising projects included Ningde Times, which raised 37.701 billion yuan, followed by Zijin Mining and Sany Heavy Industry [57]. Group 4: City and Industry Distribution - In 2025, 89 cities in mainland China and Hong Kong hosted IPO projects, with Shanghai leading at 27 projects, followed by Beijing with 21 and Shenzhen with 16 [58]. - The most active industries for IPOs were biomedicine (26 projects), hardware equipment (25 projects), and software services (22 projects), reflecting the focus on AI technology [61]. - The total fundraising in the electrical equipment sector reached 53.03 billion yuan, driven by leading companies like Ningde Times [61].

The show airs as sponsored programming and is supported by television commercial sponsors Synergy CHC (NASDAQ:SNYR) featuring its Focus Factor® Drinks, DataVault AI (NASDAQ:DVLT), HelloAxel.COM, and Sustainable Green Team (OTC: SGTM). New to The Street, the long-running business television platform showcasing emerging growth companies and market innovators, airs tonight at 6:30 PM EST on Bloomberg Television as sponsored programming. Show No. 712 features in-depth, long-form interviews with NEONC Techno ...

If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth ?Edmund Ingham is a biotech consultant. He has been covering biotech, healthcare, and pharma for over 5 years, and has put together detailed reports of over 1,000 companies. He leads the investing group Haggerston B ...